A New Drug Target That Helps Cancer Cells Escape the Immune System

Among the hallmarks of cancer is one in which cancer cells learn to avoid attacks by immune system cells. Scientists have uncovered a striking new mechanism by which cancer cells control the body's immune response. This discovery may hold potential for future cancer treatments.
New research conducted by a group of scientists from the University of East Anglia (UEA), in collaboration with the Quadram Institute, Earlham Institute and Norfolk and Norwich University Hospital, and reported in the Journal of Clinical Investigation, explained how the immune system could be used more effectively to treat cancer.
The researchers noted “how the findings will help develop new approaches to treating people with leukemia”. Their work focused on what they called “very difficult to treat” disease, acute myeloid leukemia (AML) , specifically investigating the role of macrophage LC3-associated phagocytosis in AML bone marrow.
The researchers presented scientific evidence on how AML initiation, proliferation and resistance to chemotherapy are regulated in the bone marrow environment, suggesting that any apoptotic debris remaining after cancer cell death plays a role in “regulating the immune response and growth against solid (organ) tumors” .
Activating the Immune System to Eliminate Leukemia
Scientists found that bone marrow macrophage depletion increased AML growth in in vivo (animal) experiments, and showed LC3-associated phagocytosis to be “the AML microenvironment's main route for clearing dead and dying cells through bone marrow macrophage phagocytosis in this process” . “Targeted inhibition of LC3-associated phagocytosis accelerated leukemia growth by causing apoptotic cells and bodies to accumulate,” they explained.
The team identified how to activate the immune system to fight leukemia cells and found that macrophages could be programmed to attack cancer cells through the STING protein (Stimulator of Interferon Genes), an established activator of the immune system. They also said they found that it “suppressed AML growth through a mechanism associated with increased phagocytosis” .
Study leader Dr. Stuart Rushworth of UEA's Norwich Medical School said: “Our results provide insight into how the immune system can be used to attack cancer when given the right signals. Patients can often relapse after cancer treatment because small amounts of disease remain despite chemotherapy. Our research has revealed that targeting this biological phenomenon could help eliminate leukemia from the bone marrow.”
Hope for Future Treatments
Dr. Naiara Beraza of the Quadram Institute said: “In this study, we uncovered a new mechanism by which cancer cells control the human immune response to support their own growth. These findings will enable the development of future therapies to treat leukemia.”
The researchers summarized their findings as “how macrophage LC3-associated phagocytosis of apoptotic debris in the AML bone marrow microenvironment suppresses tumor growth”.
Dr. Rushworth, who said there was growing hope for patients, stated: “Unfortunately, chemotherapy is not always enough to treat people with leukemia at present. I hope that in the future our findings will help develop treatments for people with leukemia by priming the immune response to help chemotherapy drugs work better” .
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.